104 related articles for article (PubMed ID: 17405747)
1. An acquired inhibitor that produced a delay of fibrinopeptide B release in an asymptomatic patient.
Llobet D; Borrell M; Vila L; Vallvé C; Felices R; Fontcuberta J
Haematologica; 2007 Feb; 92(2):e17-9. PubMed ID: 17405747
[TBL] [Abstract][Full Text] [Related]
2. The rate of fibrinopeptide B release modulates the rate of clot formation: a study with an acquired inhibitor to fibrinopeptide B release.
Nawarawong W; Wyshock E; Meloni FJ; Weitz J; Schmaier AH
Br J Haematol; 1991 Oct; 79(2):296-301. PubMed ID: 1958489
[TBL] [Abstract][Full Text] [Related]
3. Dysfibrinogenemia and lupus anticoagulant in a patient with recurrent thrombosis.
Al-Mondhiry H; Galanakis D
J Lab Clin Med; 1987 Dec; 110(6):726-33. PubMed ID: 3119749
[TBL] [Abstract][Full Text] [Related]
4. Sequence of fibrinogen proteolysis and platelet release after intrauterine infusion of hypertonic saline.
Nossel HL; Wasser J; Kaplan KL; LaGamma KS; Yudelman I; Canfield RE
J Clin Invest; 1979 Nov; 64(5):1371-8. PubMed ID: 500818
[TBL] [Abstract][Full Text] [Related]
5. The release of small amounts of fibrinopeptide-B (FPB) is of critical importance for the thrombin clotting time.
Holm B; Kierulf P; Godal HC
Thromb Res; 1986 May; 42(4):517-26. PubMed ID: 3715815
[TBL] [Abstract][Full Text] [Related]
6. Thrombin-induced fibrinopeptide B release from normal and variant fibrinogens: influence of inhibitors of fibrin polymerization.
Ruf W; Bender A; Lane DA; Preissner KT; Selmayr E; Müller-Berghaus G
Biochim Biophys Acta; 1988 May; 965(2-3):169-75. PubMed ID: 3365451
[TBL] [Abstract][Full Text] [Related]
7. Recombinant fibrinogen studies reveal that thrombin specificity dictates order of fibrinopeptide release.
Mullin JL; Gorkun OV; Binnie CG; Lord ST
J Biol Chem; 2000 Aug; 275(33):25239-46. PubMed ID: 10837485
[TBL] [Abstract][Full Text] [Related]
8. Autoantibody to plasma fibrinopeptide A in a patient with a severe acquired haemorrhagic syndrome.
Gris JC; Schved JF; Branger B; Aguilar-Martinez P; Vécina F; Oulès R; Sarlat C; Fourcade J
Blood Coagul Fibrinolysis; 1992 Oct; 3(5):519-29. PubMed ID: 1450318
[TBL] [Abstract][Full Text] [Related]
9. Acquired coagulation inhibitor delaying fibrinopeptide release.
Marciniak E; Greenwood MF
Blood; 1979 Jan; 53(1):81-92. PubMed ID: 758215
[TBL] [Abstract][Full Text] [Related]
10. Fibrinogen Seattle II: congenital dysfibrinogenemia with an Arg (A alpha 16)----his substitution.
Ebert RF; Schreiler WE; Bell WR
Thromb Res; 1986 Jul; 43(1):7-13. PubMed ID: 3726812
[TBL] [Abstract][Full Text] [Related]
11. Citrullinated fibrinogen shows defects in FPA and FPB release and fibrin polymerization catalyzed by thrombin.
Okumura N; Haneishi A; Terasawa F
Clin Chim Acta; 2009 Mar; 401(1-2):119-23. PubMed ID: 19109936
[TBL] [Abstract][Full Text] [Related]
12. Fibrinogen Guarenas I: partial characterization of a new dysfibrinogenemia with an altered rate of fibrinopeptide release and an impaired polymerization.
Lundberg UG; Rodriguez S; Marchi R; Ruiz-Saez A; Arocha-Piñango CL
Thromb Res; 1995 Apr; 78(2):95-106. PubMed ID: 7482436
[TBL] [Abstract][Full Text] [Related]
13. Acquired Dysfibrinogenemia Caused by Autoantibody Inhibiting Fibrin Polymerization in a Patient with MELAS Syndrome and Bleeding Tendency.
Lee N; Kim JE; Yoo HJ; Gu J; Kim H; Chung J; Koh Y; Kim HK
Ann Clin Lab Sci; 2016 Dec; 46(6):696-700. PubMed ID: 27993886
[TBL] [Abstract][Full Text] [Related]
14. Dysfibrinogenaemia characterized by abnormal fibrin monomer polymerization and normal fibrinopeptide A release.
Lane DA; Cuddigan B; VanRoss M; Kakkar VV
Br J Haematol; 1980 Mar; 44(3):483-94. PubMed ID: 6769460
[TBL] [Abstract][Full Text] [Related]
15. Fibrinogen Birmingham: a heterozygous dysfibrinogenemia (A alpha 16 Arg----His) containing heterodimeric molecules.
Siebenlist KR; Prchal JT; Mosesson MW
Blood; 1988 Mar; 71(3):613-8. PubMed ID: 3345340
[TBL] [Abstract][Full Text] [Related]
16. Two cases of dysfibrinogenemia characterized by abnormal FPB release: fibrinogen Madrid I & II.
Borrell M; Vila L; Solá J; Coll I; Gómez N; González N; Rutllant ML
Thromb Res; 1987 Mar; 45(5):591-9. PubMed ID: 3109061
[TBL] [Abstract][Full Text] [Related]
17. Steady state kinetic parameters for the thrombin-catalyzed conversion of human fibrinogen to fibrin.
Higgins DL; Lewis SD; Shafer JA
J Biol Chem; 1983 Aug; 258(15):9276-82. PubMed ID: 6409903
[TBL] [Abstract][Full Text] [Related]
18. The generation of fibrinopeptide A in clinical blood samples: evidence for thrombin activity.
Nossel HL; Ti M; Kaplan KL; Spanondis K; Soland T; Butler VP
J Clin Invest; 1976 Nov; 58(5):1136-44. PubMed ID: 993337
[TBL] [Abstract][Full Text] [Related]
19. Urokinase has direct catalytic activity against fibrinogen and renders it less clottable by thrombin.
Weitz JI; Leslie B
J Clin Invest; 1990 Jul; 86(1):203-12. PubMed ID: 2365816
[TBL] [Abstract][Full Text] [Related]
20. Substitution of tyrosine for phenylalanine in fibrinopeptide A results in preferential thrombin cleavage of fibrinopeptide B from fibrinogen.
Rooney MM; Mullin JL; Lord ST
Biochemistry; 1998 Sep; 37(39):13704-9. PubMed ID: 9753458
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
